Study of lademirsen (SAR339375) in patients with Alport Syndrome

Trial Identifier: ACT16248
Sponsor: Genzyme, a Sanofi company
Start Date: November 2019
Primary Completion Date: September 2022
Study Completion Date: September 2022
Condition: Alport Syndrome

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Australia, Queensland Herston, Queensland, Australia, 4029
Australia, Victoria Parkville, Victoria, Australia, 3050
Australia, Western Australia Nedlands, Western Australia, Australia, 6009
China Beijing, China, 100730
China Beijing, China, 100034
China Guangzhou, China, 510080
France Paris, France, 75015
France Toulouse, France, 31403
Germany Göttingen, Germany, 37075
Germany Köln, Germany, 50937
Spain, Andalucia Cordoba, Andalucia, Spain, 14004
Spain, Barcelona [Barcelona] Barcelona, Barcelona [Barcelona], Spain, 08035
Spain, Barcelona [Barcelona] Barcelona, Barcelona [Barcelona], Spain, 08025
Spain, Granada Granada, Spain, 18014
Spain, Madrid, Comunidad de Madrid / Madrid, Madrid, Comunidad de, Spain, 28040
United Kingdom, London, City of London, London, City of, United Kingdom, NW3 2QG
United Kingdom, Newcastle upon Tyne Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom, NE7 7DN
United Kingdom, Nottinghamshire Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
United States, California Los Angeles, California, United States, 90024
United States, Minnesota Minneapolis, Minnesota, United States, 55454
United States, New York New York, United States, 10032
United States, Ohio Cleveland, Ohio, United States, 44195
United States, Utah Salt Lake City, Utah, United States, 84132